US appetite voracious for tech and bio, says CIC

Andrew Williamson, CIC’s Managing Partner, is upbeat for TechBio dealflow in 2025. His firm already supports globally growing companies such as CMR Surgical, Pragmatic Semiconductor, Riverlane, Salience Labs and Microbiotica in a star-studded portfolio valued at more than £500 million.

Williamson tells Business Weekly: “We’re seeing record levels of interest from US venture investors in Cambridge Life Science and DeepTech companies. CIC has already hosted delegations from several US investors and corporations this year and their interest reflects a recognition of the quality of the science and innovation created by the Cambridge ecosystem.”

US President Donald Trump is threatening to hit imported goods with tariffs but Williamson doesn’t believe the impact will kill interest in the right propositions.

He says: “It’s too early to say whether tariffs will be implemented, at what level, in what sectors and what the EU/UK response would be. So far, we have not seen any indications that potential tariffs would affect the approach of US investors/acquirers to Cambridge companies, but we’re watching this closely.”

Entrepreneur Dr Hermann Hauser, co-founder of Amadeus Capital Partners says that he is also adopting a ‘wait and see’ approach before deliberating on any likely impact of tariffs on local, UK and European tech and bio plays. In the interim it is business as usual, says Dr Hauser.